Form 4 for TECH Bio-Techne
Accepted 2022-02-10 00:00:00 ET · period of report 2022-02-08 · accession 0001437749-22-003021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-10 | 2022-02-08 | TECH | Kelderman Kim | Pres. Diagnostics, Genom | M - OptEx | $150.78 | +1,989 | 1,989 | New | +$299.9K |
| D | 2022-02-10 | 2022-02-08 | TECH | Kelderman Kim | Pres. Diagnostics, Genom | M - OptEx | $0.00 | -1,989 | 7,511 | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-08 | M | A | 1,989 | $150.78 | 1,989 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-08 | M | D | 1,989 | $0.00 | 7,511 | D | $150.78 · — to 2025-05-01 | 1,989 Common Stock | (F1) Options to purchase 2,500 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022. |